Aesthetic Treatments During Pregnancy: What Waits, and Why

Questions about aesthetic treatments during pregnancy usually arrive as a single sentence: can this be done? For most headings there is no clean yes or no, and the reason is not caution but the evidence itself.

Controlled clinical trials are not carried out in pregnancy. For the great majority of aesthetic treatments, therefore, controlled data is limited and treatments are routinely deferred during this period. This guide sets out which heading is deferred on what grounds, which ones call for a separate assessment, and what information the conversation is built on.

What this guide does and does not do

No safety statement is made here for any treatment in pregnancy. Such a statement would assume a level of evidence that does not exist.

What is done instead is different: bringing together the known contraindications, the deferral grounds recorded on our treatment cards, and the axis on which the decision is built. In every heading the final word belongs to the joint judgement of the clinician following the pregnancy and the specialist assessing the treatment.

That distinction matters in practice. The absence of evidence of harm is not the same as a demonstration of safety. The two statements do not stand in for each other, and they are kept apart throughout this guide.

Three categories: deferral, contraindication and limited data

The headings do not collect into one list. The three categories below show why the question is not answered the same way for every treatment.

What these categories share is that none of them settles the decision within this article. They only establish the ground on which the conversation runs.

Why skin and body change during pregnancy

Part of what is asked in this period concerns the change itself rather than any treatment. Knowing where the change comes from also clarifies which heading is genuinely on the agenda.

The hormonal course is the main axis. Shifting hormone levels affect everything from the skin's capacity to hold moisture to the hair cycle, and those effects appear to different degrees in different people.

Circulation is the second axis. Increased blood volume and circulatory changes can alter skin appearance and the tendency to swelling. Most of these headings shift again as the period runs its course.

The third axis is mechanical. Tissue stretching produces change in the abdominal wall and at the skin surface, and how much of that change is lasting can only be seen after birth.

The shared consequence of these three axes is this: how much of a change seen in this period is temporary cannot be known at the outset. That uncertainty is the most practical argument against building a hurried plan.

Why no definite safety statement is used

The answer lies in research ethics and study design. Pregnant participants are excluded from clinical research because of possible risk.

What is available, therefore, comes not from planned studies but largely from case reports, observational data and mechanism-based reasoning. Information of that kind is not enough to declare a treatment suitable for this period.

The wording has to be precise here. A treatment may have no reported proven harm in pregnancy; that does not mean it is recommended during it. The accurate statement is that controlled data is limited and the treatment is deferred.

The same logic applies to breastfeeding. Because there is no data on transfer into breast milk and effect on the infant for most headings, the deferral decision is largely maintained in that period too.

Injectable headings

This is the group where the record for pregnancy and breastfeeding is clearest, and the reason given is the same throughout: there is no safety data.

Hyaluronic acid fillers are not advised during pregnancy or breastfeeding. The same record applies to injectable bio-remodelling, popularly known as a youth booster, and to hyaluronic acid skin boosters.

Mesotherapy is not carried out in this period. For botulinum toxin the record is firmer still: pregnancy and breastfeeding are stated as contraindications.

What these headings share is that deferral is positioned as a rule rather than a precaution. The plan for the treatment is rebuilt once pregnancy and breastfeeding are complete.

A frequent follow-up question is whether the area treated makes a difference. Between an injection to the face and one to the body there is no difference in the deferral decision; the recorded reason is the substance and the period, not the site.

A second follow-up question concerns quantity. When it is asked whether a small-volume treatment falls outside the rule, the answer does not change, because the recorded reason is absence of data rather than dose.

Energy and device-based headings

In device treatments, pregnancy appears directly on the contraindication list of most cards.

Radiofrequency microneedling is not carried out in pregnancy. Focused ultrasound technology is not advised in pregnancy. Body devices that deliver radiofrequency sit on the same list.

For cooling-based localised treatments, pregnancy and breastfeeding are explicit contraindications. controlled cooling of fat tissue is not planned during this period, and that rule holds regardless of the separate fact that it is not a weight-loss method in the first place.

Mechanical massage treatments present a partly different picture. Here the abdomen is not treated during pregnancy and other areas require medical assessment. The difference comes from the treatment site and the effect on circulation rather than from the mechanism.

One point worth noting across this group is that the contraindications are not limited to pregnancy. The same lists include electronic implants such as pacemakers, active infection in the area and certain chronic conditions. Pregnancy is one item on that list, not the only one.

Hair reduction and pregnancy

laser hair reduction treatment is deferred in pregnancy at the level of recommendation, and the card states the reason plainly: safety data is insufficient.

There is a distinction to hold onto here. The deferral comes from a gap in the data rather than from known harm. Knowing that difference also makes it easier to rebuild the plan once the period is over.

Hormonal change during pregnancy can increase hair growth in some areas. That picture is usually tied to the course of the period itself and is reassessed after birth.

The facts that the correct medical term is permanent hair reduction and that the treatment works only on dark, pigmented hair hold in this period as well. Both are the starting point when the plan is rebuilt.

Whether increased local hair growth turns out to be lasting is another frequent question, and it only becomes clear at the end of the period; a decision taken early rests on a picture that has not yet settled.

There is also a common worry about a course being interrupted. In a course left unfinished, the reduction already achieved is retained; what is lost is the pace of progress, and the course does not begin again from zero.

Skin care: the ingredient decides

Skin care is the one area in this guide that cannot be settled as a single heading, because the decision follows the product used rather than the name of the procedure.

Some of the serums used in device-assisted care sessions such as the hydrafacial treatment can contain ingredients that are not preferred in pregnancy; salicylic acid is the known example. That is why the card records a requirement for medical approval for this heading.

The session's other deferral grounds apply independently of pregnancy: an active cold sore, an open wound, an active infection, sunburn and a severe acne flare.

What can continue in this period is simpler. A moisturising routine and sun protection stand out more than any procedural heading, and the choice of product again calls for medical assessment.

Surgical headings

Surgery for aesthetic purposes is not planned in this period. This is not a contested area; it is the general approach to the timing of elective surgery.

For surgical headings that may arise after pregnancy, a separate timing logic applies. In surgery involving the abdominal wall, completion of breastfeeding and weight holding within the same band for a period are among the conditions looked for.

Which heading is discussed in which order after birth is the subject of a separate guide and falls outside the scope of this one.

The only surgical context that arises during this period concerns conditions unrelated to aesthetics that carry medical necessity. Their assessment does not run in the same frame and rests entirely with the clinician following the pregnancy.

Is breastfeeding assessed separately?

It is, though for most headings the outcome does not change. On the cards, pregnancy and breastfeeding are usually named together and carry the same deferral record.

The difference lies in the question itself. In pregnancy the question is built around exposure to a developing baby; in breastfeeding it is built around transfer into breast milk.

In both cases controlled data is limited. Breastfeeding is therefore not treated as a period in which treatments automatically resume.

When breastfeeding is complete and when the plan can be rebuilt is a heading discussed together with the clinician following the pregnancy.

A related subject often confused with surgical headings is change in the abdominal wall. How much of that change is lasting can only be assessed once the tissue has run its own course after birth.

A surgical decision taken during pregnancy would therefore be a decision about a picture that has not yet formed. That is why the timing is tied so plainly to the period.

Changes that may resolve on their own

Some skin and hair changes seen in this period arise from the hormonal course and can settle by themselves after birth.

Building an early intervention plan in that picture often means taking an unnecessary step against a change that would have resolved. The sound approach is to document the picture and follow the course of the period.

Where a change does not resolve, it is assessed after birth as a separate heading. The timing of that assessment again rests on medical judgement.

Three common misreadings

The first is reading deferral as a statement of risk. A treatment being deferred in this period does not mean it has been shown to be harmful; what cannot be shown is the safety itself.

The second is treating the period as one block. Although pregnancy and breastfeeding carry the same deferral record, their questions differ, and the end of each is assessed at a different time.

The third is putting individual accounts online in place of evidence. That one person had a treatment in this period without a problem does not constitute controlled data. Recorded grounds do not change with individual stories.

What information is shared before an appointment

The most critical step in this period is sharing information in full. When an appointment is being arranged, stating that you are pregnant or breastfeeding affects the whole of the treatment.

A suspected pregnancy falls within the same scope. An unconfirmed situation is handled in the same way as a confirmed one.

Alongside that, current medication, known allergies, chronic conditions and any specific warnings given by the clinician following the pregnancy are part of what is shared.

Where a pregnancy is discovered midway through a course, the same flow applies: the information is shared, the course is stopped and the plan is carried over to after the birth.

There is a practical reason for sharing this early as well. When the deferral is known in advance, the session calendar is built around it and an unnecessary journey is avoided.

How the plan is rebuilt afterwards

A deferral is not a cancellation; it shifts the plan in time. Rebuilding it does not happen in one step either.

The first step is reassessment. Because the skin and body picture may have changed during pregnancy and breastfeeding, the pre-period plan is not simply resumed.

The second step is order. Where more than one heading is on the agenda, which comes first is decided again, and that order can differ from the one set before.

The third step is expectation. The response to the same treatment can differ after this period, and discussing that possibility at the outset makes the process easier.

The fourth step is timing. Completion of breastfeeding, weight settling and, in the relevant headings, the tissue running its own course are all awaited. When those three conditions are met varies from person to person and is determined together with the clinician.

None of these four steps can be accelerated. That is precisely why the plan built at the end of the process is more accurate than the one that existed before it.

Questions asked at the assessment

A consultation in this period runs differently from a treatment planning meeting. What is discussed is not what will be done but what is being deferred and why.

The questions worth asking are clear: what is the recorded reason for this treatment in this period, how long does the deferral last, when is the assessment made afterwards and is there a care routine that can continue in the meantime.

Those answers come into focus through the joint judgement of the specialist assessing the treatment and the clinician following the pregnancy. This guide does not stand in for that judgement.

Part of the consultation is also given over to record keeping. Noting the date and course of a change that appears in this period makes the assessment after birth markedly easier.

Finally, a treatment being deferred does not mean the conversation is over. The plan is suspended, and when it will be revisited is set as the output of that consultation.

Linked guides